Industry & Policy News

[Capitol Weekly] On the table was a nearly half-billion-dollar research plan to develop revolutionary stem cell and genetic treatments for afflictions ranging from cancer to heart disease. The proposed budget boosted spending by 41 percent for 2023-24 over expenditures for the current fiscal year.

[Science Insider] The reporting requirement has often been ignored, but this time the agency took an unprecedented step: It told the scientists it wouldn’t approve any more of their research until they fell in line. After that warning and other agency actions, the pair complied, well after the 1-year deadline.

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced preliminary data from its Phase I clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.

[Iovance Biotherapeutics, Inc.] Iovance Biotherapeutics, Inc. announced that the US FDA accepted its Biologics License Application for Lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.

[Lexicon Pharmaceuticals, Inc.] Lexicon Pharmaceuticals, Inc. announced that the US FDA approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

[Inova] Inova announced a transformational gift from long-time supporters, Dwight and Martha Schar, to support the hospital system’s heart and vascular programs.